CL2003001545A1 - Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei - Google Patents

Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei

Info

Publication number
CL2003001545A1
CL2003001545A1 CL200301545A CL2003001545A CL2003001545A1 CL 2003001545 A1 CL2003001545 A1 CL 2003001545A1 CL 200301545 A CL200301545 A CL 200301545A CL 2003001545 A CL2003001545 A CL 2003001545A CL 2003001545 A1 CL2003001545 A1 CL 2003001545A1
Authority
CL
Chile
Prior art keywords
dismenorrea
quinolina
chromene
endometriosis
lei
Prior art date
Application number
CL200301545A
Other languages
English (en)
Spanish (es)
Inventor
Lin Van Oeveren Cornelis P Zhi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of CL2003001545A1 publication Critical patent/CL2003001545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL200301545A 2002-10-11 2003-08-04 Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei CL2003001545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41796802P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
CL2003001545A1 true CL2003001545A1 (es) 2005-01-07

Family

ID=31994318

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200301545A CL2003001545A1 (es) 2002-10-11 2003-08-04 Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei

Country Status (12)

Country Link
US (1) US7163946B2 (OSRAM)
EP (1) EP1554283A1 (OSRAM)
JP (1) JP2006504737A (OSRAM)
AR (1) AR040781A1 (OSRAM)
AU (1) AU2003258051A1 (OSRAM)
CA (1) CA2501834A1 (OSRAM)
CL (1) CL2003001545A1 (OSRAM)
DE (1) DE20301728U1 (OSRAM)
HK (1) HK1055059A2 (OSRAM)
MX (1) MXPA05003801A (OSRAM)
TW (1) TW200413384A (OSRAM)
WO (1) WO2004033461A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1551845A1 (en) 2002-10-11 2005-07-13 Ligand Pharmaceuticals, Inc. 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU2003258047A1 (en) 2002-10-11 2004-05-04 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
CA2074933C (en) 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JPH04316557A (ja) 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
WO1996019458A2 (en) 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
AU728178B2 (en) 1996-06-27 2001-01-04 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
SK284689B6 (sk) * 1998-02-13 2005-09-08 Abbott Laboratories Benzopyrano[3,4-f]chinolínová zlúčenina a liečivo s jej obsahom
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1551845A1 (en) * 2002-10-11 2005-07-13 Ligand Pharmaceuticals, Inc. 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU2003258047A1 (en) * 2002-10-11 2004-05-04 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS

Also Published As

Publication number Publication date
JP2006504737A (ja) 2006-02-09
AR040781A1 (es) 2005-04-20
CA2501834A1 (en) 2004-04-22
EP1554283A1 (en) 2005-07-20
TW200413384A (en) 2004-08-01
US7163946B2 (en) 2007-01-16
MXPA05003801A (es) 2005-06-08
US20040152717A1 (en) 2004-08-05
HK1055059A2 (en) 2003-12-05
AU2003258051A1 (en) 2004-05-04
WO2004033461A1 (en) 2004-04-22
DE20301728U1 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
IS6566A (is) Indólín-2-ón afleiður, framleiðsla og notkun þeirra sem mjaltavaka (ocytocin) viðtakabindlar
EE05129B1 (et) Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
IS7079A (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
FI963049L (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
ATE353909T1 (de) 3-stickstoff-6,7-dioxygenierte steroid verbindungen und verwendungen davon
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
EA200601908A1 (ru) Контроль прорывных кровотечений при пролонгированном режиме приёма гормональных контрацептивов
MXPA03004828A (es) Composiciones de poliomeros de dispersion liquida, su preparacion y su uso.
WO2006055184A3 (en) Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
ATE265497T1 (de) Hydrierte blockcopolymerzusammensetzungen und verwendungen davon
DE60020710D1 (de) Hydrierte blockcopolymerzusammensetzungen und verwendungen davon
SI1441770T1 (sl) Vaginalna formulacija lidokaina za zdravljenje uterine disritmije
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
CL2004000838A1 (es) Uso de un antagonista del receptor de aldosterona y un agente antiobesidad para preparar un medicamento util en el tratamiento de una condicion relacionada al sistema cardiovascular.
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
DE60105687D1 (de) Cyclohexanderivate, diese enthaltende Flüssigkristallzusammensetzungen und Flüssigkristallanzeigevorrichtungen
WO2006039215A3 (en) Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
TR200103285T2 (tr) Projesteron reseptörü modülatörleri olarak siklokarbamat türevleri.